Product Description
Mechanisms of Action: Phosphate Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | Germany | Ireland | Italy | Portugal | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Kidney Failure, Chronic|Hyperphosphatemia|Kidney Diseases|Dyslipidemia
Phase 2: Type 2 Diabetes
Phase 1: Hyperphosphatemia|Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01976572 |
MCI-196-E17 | P1 |
Completed |
Hyperphosphatemia|Kidney Failure, Chronic |
2014-01-01 |
2023-04-08 |
Primary Endpoints|Treatments |
|
NCT00497198 |
MCI196-19 | P2 |
Completed |
Type 2 Diabetes |
None |
2023-04-08 |
Primary Endpoints |
|
2012-002583-27 |
2012-002583-27 | P3 |
Terminated |
Hyperphosphatemia|Kidney Diseases |
2017-01-11 |
2022-03-13 |
Treatments |
|
2012-002581-12 |
2012-002581-12 | P3 |
Completed |
Hyperphosphatemia|Kidney Diseases |
2015-01-26 |
2022-03-13 |
Treatments |
|
NCT01814904 |
MCI-196-E14 | P3 |
Terminated |
Hyperphosphatemia|Kidney Failure, Chronic |
2015-01-01 |
2023-04-08 |
Primary Endpoints|Treatments |
|
2012-002582-35 |
2012-002582-35 | P3 |
Terminated |
Hyperphosphatemia|Kidney Diseases |
2014-12-17 |
2022-03-13 |
||
NCT01818687 |
MCI-196-E16 | P3 |
Terminated |
Kidney Failure, Chronic|Hyperphosphatemia |
2014-12-01 |
2023-04-08 |
Primary Endpoints|Treatments |
|
NCT01814917 |
MCI-196-E15 | P3 |
Terminated |
Hyperphosphatemia|Kidney Failure, Chronic |
2014-12-01 |
2023-04-08 |
||
NCT00451295 |
MCI-196-E09 | P3 |
Terminated |
Hyperphosphatemia|Kidney Failure, Chronic |
2011-01-01 |
2023-04-08 |
Primary Endpoints|Treatments |
|
NCT00772382 |
MCI-196-A06 | P3 |
Completed |
Hyperphosphatemia|Kidney Failure, Chronic |
2010-08-01 |
30% |
2023-04-08 |
Primary Endpoints|Treatments |
NCT00542815 |
MCI-196-E10 | P3 |
Completed |
Kidney Failure, Chronic|Hyperphosphatemia |
2010-08-01 |
32% |
2023-04-08 |
Primary Endpoints|Treatments |
2007-003364-21 |
2007-003364-21 | P3 |
Completed |
Kidney Diseases |
2010-03-20 |
2022-03-12 |
Treatments |
|
NCT00858637 |
MCI-196-E11 | P3 |
Completed |
Kidney Failure, Chronic|Dyslipidemia |
2010-03-01 |
34% |
2023-04-08 |
|
2006-003324-11 |
2006-003324-11 | P3 |
Terminated |
Kidney Diseases |
2010-01-07 |
2022-03-12 |
Treatments |
|
2006-003330-15 |
2006-003330-15 | P3 |
Completed |
Kidney Diseases |
2010-01-10 |
2022-03-12 |
Treatments |
|
2006-003323-37 |
2006-003323-37 | P3 |
Completed |
Kidney Diseases |
2009-11-06 |
2022-03-12 |
Treatments |
|
2006-006535-53 |
2006-006535-53 | P3 |
Completed |
Kidney Diseases |
2009-11-12 |
2022-03-12 |
Treatments |
|
NCT00542386 |
MCI-196-E08 | P3 |
Completed |
Dyslipidemia|Kidney Failure, Chronic|Hyperphosphatemia |
2009-11-01 |
30% |
2023-04-08 |
Primary Endpoints|Treatments |
NCT00416520 |
MCI-196-E07 | P3 |
Completed |
Hyperphosphatemia|Kidney Failure, Chronic |
2009-11-01 |
32% |
2023-04-08 |
Primary Endpoints|Treatments |
NCT00506441 |
MCI-196-A05 | P3 |
Completed |
Hyperphosphatemia|Kidney Failure, Chronic |
2009-09-01 |
30% |
2023-04-08 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/19/2023 |
PubMed |
Bile Acid Sequestrants Based on Natural and Synthetic Gels. |
|
01/01/2021 |
PubMed |
The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt with: A Review of Current and Potential Phosphate Binders (PB). |
|
06/01/2020 |
PubMed |
Phosphate binders in chronic kidney disease: an updated narrative review of recent data. |